SEATTLE, July 30, 2021, (MEDGADGET) — Europe Platelet-rich Plasma Market – Insights
PRP or Autologous platelet-rich plasma is a blood plasma concentrate enriched with a platelet count above the baseline of whole blood prepared from the patient’s own blood. It is used to help ligaments, joints, broken tendons, and muscles to recover faster.
The kits segment of the Europe platelet-rich plasma market was worth US$ 34.9 million in 2019 and is projected to grow at a CAGR of 7.1 percent to US$ 60.4 million by 2027.
Get an exclusive sample copy of the business report: https://www.coherentmarketinsights.com/insight/request-sample/3346
Drivers:
The raising occurrence of musculoskeletal wounds is expected to support the development of the European platelet-rich plasma market over the forecast period. For example, as indicated by the Study, ‘Pervasiveness of Musculoskeletal Injuries, Pain, and Illnesses in Elite Female Basketball Players, in Europe, in June 2019, the most regularly harmed body parts were lower appendages or limbs: over 60%, addressing a physical issue pace of 0.14 per athletes and a 0.2 torment rate for every competitor (during the investigation time frame).
Besides, the growing geriatric population is increasing the prevalence of knee osteoarthritis which is again expected to help in the development of the market. Maturing adds to delicate tissue degeneration and related messes, especially of the knee. For example, as indicated by the examination ‘Osteoarthritis in Europe: Impact on wellbeing status, work profitability and utilization of pharmacotherapies in five European nations’ that inspected the effect of fringe joint osteoarthritis across five European nations, UK (43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%) recorded high predominance of peripheral joint osteoarthritis, with dominant part of cases maturing 55-74 years.
In terms of value, the United Kingdom dominated the European platelet-rich plasma market in 2019, with a 23.5 percent share, led by France.
Restraints:
The absence of normalization in the arrangement and measurement of autologous blood concentrate and platelet-division procedures is the main consideration blocking the development of the market. The absence of normalization in readiness and measurements of autologous blood concentrate and platelet-division procedures lead to vulnerability about the proof to help the expanding clinical utilization of platelet-rich plasma treatment as a treatment methodology for musculoskeletal wounds, including delicate tissue and orthopedic bone wounds.
“Limited Time Offer”
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/3346
Moreover, uncertainty about therapeutic efficacy of platelet-rich plasma is also expected to hamper growth of the market. For instance, the study ‘Current Clinical Recommendations for Use of Platelet-Rich Plasma’ published in Current Reviews in Musculoskeletal Medicine in 2018, found moderate high-quality evidence that supported the use of leukocyte-rich (LR)-PRP injection for patellar tendinopathy and of PRP injection for plantar fasciitis and donor site pain in patellar tendon graft Bone-patellar tendon-bone anterior cruciate ligament reconstruction. Moreover, the review also noted insufficient evidence to routinely recommend PRP for rotator cuff tendinopathy, osteoarthritis of the hip, or high ankle sprains.
Opportunities:
The growing use of PRP for skeletal muscle injuries is expected to provide lucrative growth opportunities for market players. PRP encourages muscle regeneration by releasing anabolic growth factors from activated platelets. In skeletal muscle injuries, this decreases discomfort, swelling, and recovery time.
Furthermore, technical advances in PRP, such as improvements in production protocol (time and RPM/centrifugal force) and performance level (volume and concentration above baseline), are expected to contribute to market development.
Market Trends/Key Takeaways:
The interest for unadulterated PRP fibrin treatment has expanded fundamentally in the new past, particularly for the treatment of skin wound ulcers and in oral and maxillofacial medical procedures. The platelet-rich fibrin treatment is delegated a second era platelet concentrate, with rich platelet content and broad development factors as fibrin layers, which are liberated from any enemies of coagulants or other counterfeit bio-compound changes and advance quick and speedy up injury mending.
Because of the growing geriatric population in Europe, non-invasive or minimally invasive surgical procedures are in high demand. PRP therapy is a quick, effective, and minimally invasive treatment that uses a biological approach to ensure tissue regeneration in a short amount of time. As a result of this situation, PRP therapy for the treatment of orthopedic injuries has become very common in geriatric patients.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/europe-platelet-rich-plasma-market-2711
Key Developments:
In January 2020, SHVI PRP Therapy has launched a new website dedicated to the use of platelet-rich plasma (PRP) to treat hair loss.
IN March 2019, CollPlant, a regenerative medicine business, has extended its exclusive distribution agreement with Arthrex for Vergenix STR, an injectable gel that combines cross-linked bioengineered recombinant human type I collagen, rhCollagen, with autologous PRP to treat tendonopathy.
In January 2019, Generex Biotechnology Corporation has signed a letter of intent to purchase Medisource Partners, an FDA-registered distributor of medical and surgical products, including processing kits for bone marrow aspirates and PRP biologics during surgery.
In December 2018, The use of patients’ own bone marrow concentrate and PRP products in Regenexx’s study, which was published in the Journal of Translational Medicine, showed promising clinical results for the treatment of osteoarthritis of the knee.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Application Type
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Technological Advancement
- Regulatory Scenario
- Market Dynamics
- Europe Platelet-rich Plasma Market, By Product Type, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- Instruments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Kits
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Kits by Type
- Pure Platelet-Rich Plasma (P-PRP)
- Leukocyte-Rich Platelet-Rich Plasma (L-PRP)
- Leukocyte-Platelet-Rich Fibrin (L-PRF)
- Pure Platelet-Rich Fibrin (P-PRF)
- Kits By Origin
- Autologous Platelet-Rich Plasma
- Homologus Platelet-Rich Plasma
- Allogeneic Platelet-Rich Plasma
- Introduction
- Europe Platelet-rich Plasma Market, By Application, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- Knee
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Elbow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Foot and Ankle
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Shoulder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- CMF
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Introduction
- Europe Platelet-rich Plasma Market, By Country/Region, 2019 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Country/Regions, 2017–2026
- Germany
- The U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Introduction
- Competitive Landscape
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Other Related Reports:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837